heart disease
AstraZeneca's Brilinta Fails to Win FDA Approval
8:08AM 12/17/2010
Company News, Health Care, Pfizer, Bristol-Myers Squibb, Sanofi Aventis, Astrazeneca, Stocks in the News
The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company -- facing a severe patent cliff -- has high hopes for. If approved, it could be a multibillion-dollar blockbuster. But the FDA wants to see more analyses of results from a major study.
U.S. Hospitals Get Better at Treating Heart Attacks, Pneumonia
7:34PM 9/22/2010
U.S. hospitals are doing a more effective job treating patients for heart attacks, pneumonia and surgical procedures, an independent healthcare accreditation organization said in a report released today.
Sex reduces heart disease. An inexpensive treatment option?
10:00AM 1/26/2010
Sex at least twice per week can reduce heart disease according to a new study at the New England Research Institute in Massachusetts. Researchers tracked the sexual activity of men between 40 and 70 years old who were taking part in a long-term project called the Massachusetts Male Ageing Study,...
Health Reform Leaves Millions Uninsured, and the Rest Must Wait
6:00PM 12/23/2009
As it now exists, health-reform legislation is hardly a leap to "universal" coverage -- some 23 million Americans will be left out. Plus, neither the Senate nor the House version takes effect before 2013, leaving many newly eligible without insurance for years.
Crestor Backed by FDA for Patients With Normal Cholesterol Levels
7:30PM 12/16/2009
AstraZeneca scored a win on Tuesday, when a Food and Drug Administration advisory panel recommended broader use of Crestor, the company's cholesterol-lowering drug. The panel recommended that those with low cholesterol use the drug, following studies finding that Crestor reduces the risk of heart disease even in those with normal cholesterol levels.
Even without eating junk food mummies had heart disease, too
3:45PM 11/19/2009
Heart disease, it seems, doesn't discriminate, striking not only both men and women. Now, scientists have learned not even Pharaohs were spared of hardened arteries.
And they developed heart disease despite the absence of super-size fries paired with a sugary soda and greasy burgers, one of...
When the bestselling book French Women Don't Get Fat came out in 2004, it was yet another occasion to begrudge Gallic females, who could always say oui to pâté, brie, and crème brûlée without ever having to get their Hermès skirts altered. It didn't help that...
It's not easy being first. Biotech company Geron (GERN) had to wait more than a year before getting the green light from federal regulators in January to begin the first study using human embryonic stem cell-based therapies in humans. The early-stage trial is looking at the safety of its drug...
When I was growing up, it seemed like everything that I liked ended up being bad for me. From playing in the mud, which destroyed my clothes, to eating pre-sweetened cereal, which left me climbing the walls, it was almost a foregone conclusion that anything that brought me pleasure was also going...
More Stories
Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.07 | -0.11 -1.34% | 254.23M | |
| 2.19 | +0.25 +12.89% | 122.18M | |
| 18.88 | -0.26 -1.33% | 109.55M | |
| 12.44 | -0.25 -1.97% | 52.49M |
% Gainers
| 31.68 | +7.78 +32.55% | 18.42M | |
| 89.96 | +13.57 +17.76% | 13.27M | |
| 2.19 | +0.25 +12.89% | 122.18M | |
| 10.50 | +1.10 +11.70% | 3.07M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Greece's grim choice: deep budget cuts or...
- Greek premier defends bailout deal, painful...
- Faces beyond the numbers of long-term...
- Staff at The Sun tabloid arrested in bribe...
- Obama budget: New spending with recycled tax...
- Obama budget seeks to boost trade enforcement
- As Facebook IPO nears, the case for dull stocks
- Turbo-traders take Bank of America for a ride
- Getting paid $35,000 to short sell
- What the $26B settlement means for you
- Investing your emergency cash: Return vs. risk
- First Premier's $400-a-year credit card
- Big banks' bloated mortgage tab
- Fewer young adults hold jobs than ever before
- Government assistance expands
- Bob Rodriguez: The best advice I ever got
- 24/7 Wall St. Top Analyst Calls of the Week (AONE, ALU, AMSC, NLY, AAPL, CSCO, COH, CSTR, COP, DLR, IBM, LF, MMM, M, OPEN, POST, SIRI, SOHU, TRLG, ZOLT)
- The Force: Star Wars Franchise Worth Over $30 Billion and Growing
- 24/7 Wall St. Closing Bell (COP, GILD, AMSC, MA, COH, LNKD, ATVI, CPST, GPRE, KONA, TRLG, LGF, MOVE, NBL, PCYC, ALU, FLIR, RUTH, FSLR, CIE, TBAC, RPXC, AMRS)
- Mid-day Movers (CIE, AMRS, IPSU, MOVE, LNKD)
- Petrobras Shares Volatile on $225 Billion Development Plan (PBR)
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
Follow Us
